8EV.F EVGEN PHARMA PLC LS-0025
- Market cap
- EUR 5.29M
- P/E
- -
- P/B
- 0.33x
- ROE
- -130.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Mar 2026.
Is 8EV.F undervalued?
Graham numberThe Graham number of EVGEN PHARMA PLC LS-0025 cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
EVGEN PHARMA PLC LS-0025 fundamental analysis
No fundamental analysis for EVGEN PHARMA PLC LS-0025 yet.
EVGEN PHARMA PLC LS-0025 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About EVGEN PHARMA PLC LS-0025
Theracryf Plc, a clinical stage therapeutics company, engages in the development of therapeutics for behavioural brain disorders. The company develops orexin-1 antagonist for the treatment of binge eating disorder and anxiety; and atypical dopamine transporter inhibitor (DAT) to treat fatigue and narcolepsy. It also develops SFX-01 for the treatment of cancers, neurodevelopmental disorders, and other diseases. The company was formerly known as Evgen Pharma plc and changed it…
Full company profileEVGEN PHARMA PLC LS-0025 financial statements
EVGEN PHARMA PLC LS-0025 annual financial statements (GBP; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 0.00 | 442K | 396K | 0.00 | 0.00 |
| Operating Income | -3.19M | -5.07M | -3.56M | -2.12M | -3.69M |
| EBITDA | -3.18M | -5.06M | -3.55M | -2.05M | -3.67M |
| Net Income | -2.73M | -4.04M | -3.14M | -1.94M | -3.53M |
| EPS | -0.01 | -0.01 | -0.01 | 0.00 | 0.00 |
| Balance Sheet | |||||
| Total Assets | 9.64M | 6.17M | 3.06M | 7.63M | 4.81M |
| Total Liabilities | 411K | 833K | 721K | 1.66M | 2.10M |
| Shareholders' Equity | 9.23M | 5.34M | 2.34M | 5.97M | 2.72M |
| Cash & Short-term Investments | 4.51M | 5.00M | 2.00M | 2.11M | 471K |
| Cash Flow | |||||
| Operating Cash Flow | -2.58M | -4.13M | -3.00M | -2.37M | -2.66M |
| Capital Expenditure | 3.00K | 1.00K | 0.00 | 0.00 | 17.0K |
| Free Cash Flow | -2.59M | -4.13M | -3.00M | -2.37M | -2.67M |
| Ratios | |||||
| ROE | -29.6% | -75.7% | -134.0% | -32.5% | -130.0% |
| ROA | -28.3% | -65.5% | -102.4% | -25.4% | -73.3% |
| Net Profit Margin | - | -914.7% | -792.2% | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
EVGEN PHARMA PLC LS-0025 dividends
EVGEN PHARMA PLC LS-0025 has not paid dividends in the last 5 fiscal years.
Who owns EVGEN PHARMA PLC LS-0025
- Insiders 49.66%
- Institutions 26.13%
- Public & others 24.21%
- Shares outstanding 2.15B
- Free float 1.42B
EVGEN PHARMA PLC LS-0025 company profile
- Company name
- EVGEN PHARMA PLC LS-0025
- Ticker
- 8EV.F
- ISIN
- GB00BSVYN304
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 9
- Fiscal year end
- March
- Address
- Alderley Park, Nether Alderley, United Kingdom, SK10 4TG
- Phone
- 44 1625 315 090
- Website
- theracryf.com
About EVGEN PHARMA PLC LS-0025
Theracryf Plc, a clinical stage therapeutics company, engages in the development of therapeutics for behavioural brain disorders. The company develops orexin-1 antagonist for the treatment of binge eating disorder and anxiety; and atypical dopamine transporter inhibitor (DAT) to treat fatigue and narcolepsy. It also develops SFX-01 for the treatment of cancers, neurodevelopmental disorders, and other diseases. The company was formerly known as Evgen Pharma plc and changed its name to Theracryf Plc in April 2024. Theracryf Plc was incorporated in 2014 and is headquartered in Nether Alderley, the United Kingdom.
EVGEN PHARMA PLC LS-0025 management
4- Dr. Huw Jones BSc, Ph.D.CEO & Executive Director · born 1959
- Mr. Toni Markus Antero HaenninenCFO & Director · born 1977
- Dr. Helen Kuhlman Ph.D.Chief Operating Officer
- Dr. Glen Clack FFPM, M.D.Chief Medical Officer